

# Marica Meroni

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4388290/marica-meroni-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

1,697  
citations

23  
h-index

41  
g-index

58  
ext. papers

2,449  
ext. citations

6.5  
avg, IF

4.92  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 41 | The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , <b>2016</b> , 150, 1219-1230.e6 | 13.3 | 347       |
| 40 | MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , <b>2017</b> , 7, 4492  | 4.9  | 131       |
| 39 | Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 505-515 | 13.4 | 113       |
| 38 | Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , <b>2018</b> , 10,                                     | 17.5 | 85        |
| 37 | Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , <b>2016</b> , 48, 384-91   | 1.5  | 78        |
| 36 | PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5212-5222                                    | 5.6  | 71        |
| 35 | The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , <b>2016</b> , 63, 787-98                    | 11.2 | 70        |
| 34 | miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,                                    | 6.3  | 70        |
| 33 | Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , <b>2020</b> , 31, 406-421.e7   | 24.6 | 69        |
| 32 | Alcohol or Gut Microbiota: Who Is the Guilty?. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,   | 6.3  | 59        |
| 31 | Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 775-782   | 13.4 | 50        |
| 30 | Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,   | 6.3  | 44        |
| 29 | Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 3682                            | 4.9  | 42        |
| 28 | The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. <i>Nutrients</i> , <b>2019</b> , 11,                                       | 6.7  | 42        |
| 27 | Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <i>Clinical Science</i> , <b>2017</b> , 131, 1301-1315 | 6.5  | 38        |
| 26 | Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , <b>2020</b> , 52, 102658   | 8.8  | 36        |
| 25 | Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. <i>Gut</i> , <b>2020</b> , 69, 1855-1866                                 | 19.2 | 34        |

|    |  |      |    |
|----|--|------|----|
| 24 | The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 229-42                              | 4.2  | 32 |
| 23 | Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2660-2669 | 5.6  | 30 |
| 22 | Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , <b>2018</b> , 2, 666-675 | 6    | 30 |
| 21 | gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , <b>2019</b> , 60, 1144-1153  | 6.3  | 27 |
| 20 | FKlotho gene variation is associated with liver damage in children with NAFLD. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 411-419  | 13.4 | 27 |
| 19 | Nutrition and Genetics in NAFLD: The Perfect Binomium. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3  | 26 |
| 18 | mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. <i>Nutrients</i> , <b>2019</b> , 11,   | 6.7  | 19 |
| 17 | Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 117, 154708   | 12.7 | 19 |
| 16 | MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. <i>EBioMedicine</i> , <b>2020</b> , 57, 102866   | 8.8  | 17 |
| 15 | Notch signaling and progenitor/ductular reaction in steatohepatitis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187384  | 3.7  | 16 |
| 14 | Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3  | 8  |
| 13 | Genetics Is of the Essence to Face NAFLD. <i>Biomedicines</i> , <b>2021</b> , 9,   | 4.8  | 7  |
| 12 | TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2021</b> ,                      | 7.9  | 6  |
| 11 | The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 6  |
| 10 | From Environment to Genome and Back: A Lesson from Mutations. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3  | 5  |
| 9  | Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2020</b> , 1865, 158765                   | 5    | 4  |
| 8  | Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. <i>Exploration of Medicine</i> , <b>2020</b> , 1, 218-243  | 1.1  | 3  |
| 7  | MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. <i>Journal of Internal Medicine</i> , <b>2021</b> ,   | 10.8 | 3  |

|   |   |      |   |
|---|---|------|---|
| 6 | Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , <b>2021</b> ,  | 6    | 3 |
| 5 | NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP). <i>Peptides</i> , <b>2021</b> , 141, 170552   | 3.8  | 3 |
| 4 | Impact of natural neuromedin-B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 167-177  | 7.1  | 2 |
| 3 | Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of .. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabh3831  | 17.5 | 2 |
| 2 | Impact of Sarcopenia and Myosteatorsis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.. <i>Biomedicines</i> , <b>2022</b> , 10, | 4.8  | 1 |
| 1 | The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. <i>EBioMedicine</i> , <b>2021</b> , 65, 103249  | 8.8  | 1 |